Provider : Sadif Analytics Prime
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
EU approves Roche Holding AG’s Avastin for platinum-resistant recurrent ovarian cancer
Roche Holding AG:Says EU approves Roche’s Avastin for platinum-resistant recurrent ovarian cancer.Approval based on results of phase III AURELIA study which involved women with recurrent, platinum-resistant ovarian cancer who received either chemotherapy or Avastin in combination with chemotherapy.
Latest Developments forRoche Holding AG
- Novartis discussing Roche Holding AG stake sale, but not imminent -sources - Reuters
- Roche Holding confirms FY 2016 outlook
- Roche Holding says FDA grants venetoclax accelerated approval for people with hard-to-treat type of leukemia
- Roche Holding says FDA fast tracks atezolizumab in specific type of lung cancer
Latest Key Developments inPharmaceuticals
- Share this
- Digg this